US5853709A - Shaving composition and method for preventing pseudofolliculitis barbae - Google Patents
Shaving composition and method for preventing pseudofolliculitis barbae Download PDFInfo
- Publication number
- US5853709A US5853709A US08/766,395 US76639596A US5853709A US 5853709 A US5853709 A US 5853709A US 76639596 A US76639596 A US 76639596A US 5853709 A US5853709 A US 5853709A
- Authority
- US
- United States
- Prior art keywords
- composition
- weight
- agent
- bacteriostatic
- shaving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 42
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 239000002904 solvent Substances 0.000 claims abstract description 26
- 239000002562 thickening agent Substances 0.000 claims abstract description 23
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 20
- 230000000027 hemostyptic effect Effects 0.000 claims abstract description 19
- 210000004209 hair Anatomy 0.000 claims abstract description 18
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 13
- 230000000699 topical effect Effects 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000004018 waxing Methods 0.000 claims abstract description 7
- 239000006210 lotion Substances 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 24
- 229960002799 stannous fluoride Drugs 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 230000003750 conditioning effect Effects 0.000 claims description 14
- 239000003906 humectant Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 11
- 229940086555 cyclomethicone Drugs 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 210000004013 groin Anatomy 0.000 claims description 8
- 210000000689 upper leg Anatomy 0.000 claims description 8
- 229920003118 cationic copolymer Polymers 0.000 claims description 7
- 125000002091 cationic group Chemical group 0.000 claims description 7
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 6
- 229920006322 acrylamide copolymer Polymers 0.000 claims description 5
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- 229960004711 sodium monofluorophosphate Drugs 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 241000208680 Hamamelis mollis Species 0.000 claims description 3
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 229960005274 benzocaine Drugs 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229940118846 witch hazel Drugs 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- ZSUXOVNWDZTCFN-UHFFFAOYSA-L tin(ii) bromide Chemical compound Br[Sn]Br ZSUXOVNWDZTCFN-UHFFFAOYSA-L 0.000 claims 10
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 description 33
- 210000003491 skin Anatomy 0.000 description 31
- 239000000047 product Substances 0.000 description 23
- 238000011282 treatment Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 16
- 239000000499 gel Substances 0.000 description 14
- 230000001815 facial effect Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 239000003205 fragrance Substances 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 239000000084 colloidal system Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 206010033733 Papule Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 206010037888 Rash pustular Diseases 0.000 description 5
- 230000002951 depilatory effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 208000029561 pustule Diseases 0.000 description 5
- 239000008257 shaving cream Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000004909 Moisturizer Substances 0.000 description 4
- 229920000289 Polyquaternium Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002553 poly(2-methacrylolyloxyethyltrimethylammonium chloride) polymer Polymers 0.000 description 2
- 229940115476 ppg-1 trideceth-6 Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical compound [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010052899 Ingrown hair Diseases 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000008341 cosmetic lotion Substances 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- BPXGKRUSMCVZAF-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)decanamide Chemical compound CCCCCCCCCC(=O)N(CCO)CCO BPXGKRUSMCVZAF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940013123 stannous chloride Drugs 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/02—Shaving preparations
Definitions
- This invention relates to shaving cream compositions and methods for allowing the shaving of hair-bearing areas of the human body without causing or aggravating the skin disease pseudofolliculitis barbae.
- Pseudofolliculitis barbae is a chronic inflammatory condition of the hair-bearing areas of the lower face and neck as well as other hairy skin areas (such as the nuchal, bikini and leg areas) and is characterized by the following: irritating "bumps", soreness, itchiness, and dark or red discolored spots of the affected skin areas.
- the condition is a direct result of shaving, occurring in more than 80% of African Americans and about 22% of other racial groups. It may lead to infection, permanent dark discoloration, scarring, and even keloid formation in some individuals.
- PFB is also commonly referred to as "razor burns" and "ingrown hairs”.
- PFB results in most instances from an inflammatory response incited by hairs which are "ingrown” or trapped underneath the cornified layer (stratum corneum) of the skin, or hairs which emerge from their follicles with a sharp curl and whose points penetrate back into the skin to form a "pseudo follicle" (thus, "pseudofolliculitis”).
- the hair trapped beneath the skin or the ends which have repenetrated the skin from the surface cause the eruption of swollen pus-filled lesions known as perifollicular papules which blanket the shaved skin area. This reaction is commonly called “bumping up”.
- PFB can be caused not only by shaving but also by waxing and tweezing the hairy area.
- a shaving lotion or cream composition for use by human subjects suffering from or prone to development of PFB comprising a bacteriostatic/hemostyptic agent, a solvent, a volatile silicone and a thickener.
- the composition may also contain a nonionic or cationic polymeric conditioning agent and a surfactant, as well as fragrances, cooling agents, coloring agents, topical anesthetics, preservatives and other conventional ingredients used in topical cosmetic or toiletry formulations.
- the method of the invention for treating or preventing PFB in humans comprises the application of a shaving composition comprising a bacteriostatic/hemostyptic agent to a hairy skin area, particularly a skin area prone to or already exhibiting the symptoms of PFB, prior to the shaving, waxing or tweezing of that skin area.
- the composition may be applied alone before hair removal or as a pre-treatment followed by application of a conventional shaving cream or gel.
- FIG. 1 is a bar graph reflecting the mean facial lesion count on the treated and untreated sides of the faces of eighteen (18) male human subjects who for two (2) weeks shaved one side of their faces using a lotion composition of the invention and the other side using the same composition vehicle but without the active ingredient, and then used the active lotion on both sides of their faces for three (3) weeks.
- FIG. 2 is a bar graph reflecting the mean facial lesion count on the treated and untreated sides of the thigh/groin areas of six (6) female human subjects who for two (2) weeks shaved one side of their thigh/groin areas using a lotion composition of the invention and the other side using the same composition vehicle but without the active ingredient, and then used the active lotion on both sides of the test areas for three (3) weeks.
- FIG. 3 is a bar graph reflecting the mean facial lesion count on the treated and untreated sides of the faces of twenty (20) human subjects who for three (3) weeks shaved one side of their faces using a standard shave gel alone and the other side with a bacteriostatic/hemostyptic agent (stannous fluoride) in a stabilizing glycerin base applied as a pre-treatment prior to application of the standard gel.
- a bacteriostatic/hemostyptic agent sodium fluoride
- the novel shaving composition of the invention may take any physical form known in the art for compositions applied to hair-bearing areas of the skin prior to removal of hair from those areas by shaving, waxing, tweezing or other means of hair removal.
- Such physical forms include creams, lotions, gels, liquids, and the like.
- the preferred embodiments of the novel composition are a shaving lotion or shaving cream.
- the lotion or cream composition of the invention comprises as its active ingredient a bacteriostatic/hemostyptic compound, preferably selected from the group consisting of stannous fluoride, stannous chloride, salicylic acid, alpha hydroxy acids and sodium monofluorophosphate.
- the active ingredient is preferably dissolved or dispersed in a stabilizing vehicle, for example, glycerin or propylene glycol, and is present in the shaving composition in a weight concentration range of about 0.01-5%, and preferably about 0.1-2%, based on the weight of the total composition.
- the bacteriostatic/hemostyptic agent or agents included in the shaving compositions of the invention play an important role in the prevention/treatment of PFB. These agents inhibit bacterial growth and swelling upon nicking or scratching of the skin during shaving. These actions help suppress the development or aggravation of razor bumps and assist the healing process.
- the preferred bacteriostat for purposes of the invention is stannous fluoride which is currently used safely and effectively in tooth pastes and gels and in aqueous solutions for topical application.
- composition of the invention further comprises as pharmaceutically inert ingredients one or more aqueous or water-miscible solvents, volatile silicones and thickening agents.
- the lotion or cream composition of the invention also comprises in its preferred embodiments one or more ingredients from each of the following categories: humectants; nonionic or cationic polymeric conditioning agents; surfactants; and topical anesthetic agents, and may also include as desired for particular formulations fragrances, cooling aid ingredients, coloring agents, emulsifiers and preservatives.
- the solvents used in the composition of the invention may be water, an alcohol such as ethyl or isopropyl alcohol or a mild, water-miscible astringent such as witch hazel.
- the solvent components of the shaving composition may also comprise a mixture of one or more of the foregoing solvents, in proportions deemed appropriate by those skilled in the art of formulating cosmetic lotions and creams.
- the precise weight percentage of the solvent or solvent mixture in the cream or lotion composition and the proportion of various solvents used in the case of a solvent mixture will depend on various factors, including, by way of illustration, the desired thickness or viscosity of the finished composition, the identity and quantity of the ingredients to be dissolved in a given formulation of the composition and the sensitivity or disease (PFB) status of the skin to be treated.
- PPF sensitivity or disease
- a milder and less irritating solvent system should be used for the most sensitive skin while a more astringent solvent can be employed for less sensitive or less affected skin areas.
- the volatile silicones used in the composition of the invention are low-viscosity cyclomethicone fluids which are clear, essentially odorless and non-toxic, non-greasy and non-stinging.
- These cyclomethicone fluids generally comprise a mixture of dimethylcyclosiloxane trimers, tetramers and pentamers.
- Thickening agents for use in the novel compositions include any thickening or viscosity-increasing agents which are appropriate for use in a topical cream or lotion cosmetic formulation, especially cationic polymers and copolymers, e.g., SALCARE SC-96 (Allied Colloids Inc.), a cationic copolymer of Polyquaternium 37 with propylene glycol dicaprylate dicaprate and PPG-1 Trideceth-6 ester.
- Alternative thickening agents include SALCARE SC-91, SC-92 and SC-95 (all from Allied Colloids).
- the preferred humectant for use in the novel compositions is glycerin, but other humectants such as sorbitol, propylene glycol, hexylene glycol and hydrogenated starch hydrolysate may be used, as well as any other humectant compositions known in the art as suitable for use in topical shave lotions or creams.
- Superol Glycerin, USP is used as the humectant ingredient and also serves as the primary solvent or dispersing vehicle for the bacteriostatic, hemostyptic ingredient stannous fluoride.
- Nonionic and cationic polymeric agents used in the invention are preferably acrylamide polymers or copolymers. These polymers serve as conditioning agents to soften beard and body hairs and prevent their re-entry or re-penetration into the skin, and also help to soften and condition the skin.
- conditioning agents suitable for use in the invention include SALCARE SC-60 (Allied Colloids Inc., Suffolk, Va.), which is copolymer of acrylamidopropyl-trimonium chloride and acrylamide copolymer and SALCARE SC-10 (Allied Colloids) or MERQUAT 550 (Calgon Corp., Pittsburgh, Pa.), both of which are aqueous solutions of Polyquaternium 7, a cationic copolymer of dimethyldiallyammonium chloride and acrylamide.
- Alternative polymeric conditioning agents include Polyquaternium 4, Polyquaternium 10, Polyquaternium 39, hydroxyethylcellulose and guar gum.
- Sufactants useful in the novel lotion or cream compositions include, in particular, those which are self-solubilizing in aqueous systems and which also provide lubricity and impart a silky texture on skin and hair.
- a preferred surfactant is AVAMID 150 (Mona Industries, Paterson, N.J.), a mixture of avocadamine DEA and avocado oil. This surfactant also helps stabilize stannous fluoride in glycerin and maintains the activity level of that agent by raising the pH of the composition to a less acidic level.
- Other amide diethanolamine surfactants which may be used include lauramide DEA, soyamide DEA, cocamide DEA, and capramide DEA.
- Preservatives for the novel composition may be any standard cosmetic preservative, particularly those such as methyl paraben and imidazolidinyl urea which in low concentrations do not irritate sensitive or PFB-diseased skin but which effectively inhibit bacterial and fungal growth in the composition.
- concentration ranges by weight of the above ingredients are shown below. In each case, the percentage ranges given are for the aggregate of all ingredients coming within the listed category (e.g., all solvents or all silicones).
- Optional ingredients which may be included in certain embodiments of the novel shaving compositions include fragrances of the type conventionally used in shaving creams and lotions intended for sensitive or allergic skin, coloring agents selected from FDA-approved cosmetic pigments and color additives, and preservatives and other additives intended to increase stability and shelf life.
- a further category of optional ingredients in the composition are topical anesthetic agents, particularly lidocaine and benzocaine. These agents not only reduce the pain and irritation experienced by PFB-sufferers both during and after shaving, they also possess some bacteriostatic and hemostatic properties.
- composition of the invention may also contain a cooling aid component comprising skin cooling agents (e.g., peppermint oil and menthol) and/or fragrance to provide a fresh sensation and scent on the skin which remains after shaving.
- skin cooling agents e.g., peppermint oil and menthol
- fragrance to provide a fresh sensation and scent on the skin which remains after shaving.
- the ingredients of the shaving lotion or cream compositions may be mixed and formulated to produce the finished product by any means known to those skilled in the art of cosmetic and toiletry formulations.
- water or other aqueous solvent or solvent system is added first to a manufacturing tank and then the nonionic or cationic polymeric agents, if any, are added with constant stirring so that they are dispersed well in the solvent, whereupon warming of the batch in the tank is begun to maximize gelation.
- the bacteriostatic agent (in its vehicle) and volatile silicone are added to the tank together with any humectant being utilized, and further mixing is performed until the batch is uniform and free of undissolved particles.
- the thickening agent or agents are added, again under continuous mixing, until the batch becomes thick and uniform.
- a surfactant may then added to the batch and mixed well, whereupon the batch turns creamier and whiter. Any cooling aids, fragrances, preservatives and the like may be added following the surfactant with further mixing until the batch is uniform and homogeneous.
- the present invention also comprehends a method of treating or preventing PFB using the novel shaving lotion or cream compositions.
- the method comprises the application to a hairy skin area of a human subject suffering from or prone to the development of PFB, prior to shaving, waxing or tweezing the hairy area, of a thin coating of the novel composition.
- Application of the shaving lotion or cream of the invention may be followed directly by shaving, waxing or tweezing, or a further shaving composition, such as a standard shaving cream or gel, may be applied on top of the novel composition prior to initiating the hair removal process.
- the composition of the invention acts as a pre-shave treatment lotion or cream, but still serves to ameliorate any aggravation or eruption of PFB lesions.
- the manufacturing procedure used to produce each of the shaving lotion compositions was as follows:
- compositions produced were of a creamy lotion consistency and were non-oily, non-staining and had a pleasant fragrance and feel.
- Test shaving lotion composition of Example 1
- Inactive vehicle composition of Example 1 without stannous fluoride
- the subjects had pre-existing PFB consisting of at least 20 lesions (papules and/or pustules) bilaterally spread on the face and neck in males and the thigh/groin area in females, as determined by a dermatologist.
- PFB pre-existing PFB consisting of at least 20 lesions (papules and/or pustules) bilaterally spread on the face and neck in males and the thigh/groin area in females, as determined by a dermatologist.
- PFB lesions follicular papules and pustules
- the lesion counts were made and recorded separately for the treated and untreated (inactive vehicle only) sides of the face and neck or thighs and groin at Week 0-(pre-treatment), Weeks 1 and 2 (during initial treatment phase) and at weeks 3, 4 and 5 after crossover to active formulation only. Only active lesions were counted, with all macular and other post-inflammatory lesions disregarded.
- each subject was provided with a gentle facial soap (Purpose®), a PFB razor (Gillette Sensor Excel®) and the test products (the composition of Example 1 and a second composition containing the same vehicle but no active ingredient).
- a gentle facial soap Purpose®
- PFB razor Gillette Sensor Excel®
- the test products the composition of Example 1 and a second composition containing the same vehicle but no active ingredient.
- Prior to daily shaving each subject washed his face or her thigh and groin area with soap and rinsed with warm water, followed by gentle towel blotting to remove excess water.
- the active test product was then applied to the right side of the test area in half the subjects and to the left side in the remaining half, and left on for 3 1/2 minutes. Both groups applied the inactive product to the other side of their test areas. Both sides of the test area were then shaved with the PFB razor. After the completion of shaving, the entire test area was rinsed and patted dry to remove excess water, but leaving the skin moist. Subjects with ordinary dry skin
- FIGS. 1 and 2 The results of the study in terms of mean lesion counts are illustrated in FIGS. 1 and 2.
- Test product (stannous fluoride 0.6% in a glycerin base)
- the subjects had pre-existing PFB consisting of at least 20 lesions (papules and/or pustules) bilaterally spread on the face and neck as determined by a dermatologist.
- PFB lesions follicular papules and pustules
- the lesion counts were made and recorded separately for the right and left sides of the face and neck at Week 0 (pre-treatment), Weeks 1, 2 and 3 (during treatment) and at post-treatment. Only active lesions were counted, with all macular and other post-inflammatory lesions disregarded.
- Each subject was provided with a gentle facial soap (Purpose®), a PFB razor, a shaving gel/lather (Edge Ultimate® for Sensitive Skin) and the test product.
- a gentle facial soap Purpose®
- PFB razor a PFB razor
- a shaving gel/lather Edge Ultimate® for Sensitive Skin
- the test product was then applied to the right side of the face and neck in ten subjects and to the left side of the face and neck in the remaining ten subjects. In each case the product was applied for two minutes, rinsed off and then re-applied.
- the conventional shaving gel was then applied first on the side of the face without the test product and then on the treated side of the face, and the untreated side was shaved first followed immediately by shaving of the treated side. After the completion of shaving, the entire face was rinsed and patted dry to remove excess water, but leaving the skin moist. Subjects with ordinary dry skin were allowed to use Cetaphil® moisturizing cream over the entire face as necessary.
- test product could not be used alone as a pre-shave composition, as in Example 4, because the glycerin base with stannous fluoride, in the absence of the other components of the novel composition (solvents, silicones and thickeners) did not possess the necessary physical characteristics to serve as a lubricating shave product.
- any cosmetically elegant composition with suitable characteristics for a shaving lotion, cream or gel (such compositions being well-recognized by those of ordinary skill in the art) which contains the requisite concentration of 0.1-5% by weight of stannous fluoride or of the other topical bacteriostatic/hemostyptic agents of the invention may be used in a method for preventing and/or treating PFB.
- compositions and methods which achieve the various objects of the invention and which are well adapted to meet the conditions of practical use.
Abstract
Description
______________________________________ % of composition (w/w) INGREDIENT BROAD RANGE PREFERRED RANGE ______________________________________ Bacteriostats 0.01-5 0.1-2 (stannous fluoride, etc.) Solvents 50-90 70-90 Volatile Silicones 0.5-10 2-8 Thickening Agents 0.5-5 1-4 Humectants 0-15 2-10 Conditioning Agents 0-15 1-12 Surfactants 0-10 0.1-3 Preservatives 0-2.0 0.1-1.0 ______________________________________
TABLE 1 ______________________________________ % of composition (w/w) Ingredients Example 1 Example 2 Example 3 ______________________________________ Water QS QS QS SALCARE SC-60 (Allied Colloids) 1.00 -- 1.00 Acrylamidopropyltrimonium Chloride/acrylamide Copolymer SALCARE SC-10 (Allied Colloids) -- 12.00 -- Polyquaternium-7 (8.50%) Glycerin, 99.5% 5.00 5.00 5.00 Stannous Fluoride, USP 1.00 1.00 1.00 OSI FLUID VS-7207 OR 5.00 5.00 5.00 DOW CORNING 244 FL Cyclomethicone SALCARE SC-96 (Allied Colloids) 2.50 2.50 2.50 Polyquaternium 37/propylene Glycol Dicaprylate Dicaprate (and) PPG-1 Trideceth-6 AVAMID 150 (Mona Industries) 0.50 0.50 0.60 Avocadamide DEA (And) Avocado Oil Cooling Aid 0.10 0.10 0.10 Methyl Paraben -- -- 0.10 Imidazolidinyl Urea -- -- 0.15 ______________________________________
______________________________________ Cooling Aid Ingredients % (w/w) ______________________________________ Peppermint Oil (Triple Distilled) 89 Menthol Crystals, U.S.P. 1 FRESCOLAT ML (Haarmann & Reimer) 5 (Menthyl Lactate) FLORAL 85% BENZYL ALCOHOL (TFF Corp.) 5 (Fragrance and Benzyl Alcohol) ______________________________________
______________________________________ Appearance White creamy lotion pH: 3.80-4.50 Viscosity 55-75 scale reading (LVT,spindle # 4, 12 RPM, 1 minute). NVM @ 105° C. 9.00-9.20 2 hours Total Reducing 0.060-0.065 meq/g Substances: ______________________________________
Claims (52)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/766,395 US5853709A (en) | 1996-12-12 | 1996-12-12 | Shaving composition and method for preventing pseudofolliculitis barbae |
NZ336621A NZ336621A (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
BR9713576-3A BR9713576A (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method to prevent pesbaofolliculitis barbae. |
CA002274812A CA2274812A1 (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
APAP/P/1999/001601A AP9901601A0 (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofoliculitis barbae. |
JP52677998A JP2001505913A (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis |
IL13042297A IL130422A0 (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
AU55146/98A AU5514698A (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
EP97951521A EP0957895A4 (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
PCT/US1997/022044 WO1998025581A1 (en) | 1996-12-12 | 1997-12-08 | Shaving composition and method for preventing pseudofolliculitis barbae |
ZA9711100A ZA9711100B (en) | 1996-12-12 | 1997-12-10 | Shaving composition and method for preventing pseudofolliculitis barbae. |
NO992851A NO992851L (en) | 1996-12-12 | 1999-06-11 | Shaving preparation and method for preventing pseudofolliculitis barbae |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/766,395 US5853709A (en) | 1996-12-12 | 1996-12-12 | Shaving composition and method for preventing pseudofolliculitis barbae |
Publications (1)
Publication Number | Publication Date |
---|---|
US5853709A true US5853709A (en) | 1998-12-29 |
Family
ID=25076313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/766,395 Expired - Fee Related US5853709A (en) | 1996-12-12 | 1996-12-12 | Shaving composition and method for preventing pseudofolliculitis barbae |
Country Status (12)
Country | Link |
---|---|
US (1) | US5853709A (en) |
EP (1) | EP0957895A4 (en) |
JP (1) | JP2001505913A (en) |
AP (1) | AP9901601A0 (en) |
AU (1) | AU5514698A (en) |
BR (1) | BR9713576A (en) |
CA (1) | CA2274812A1 (en) |
IL (1) | IL130422A0 (en) |
NO (1) | NO992851L (en) |
NZ (1) | NZ336621A (en) |
WO (1) | WO1998025581A1 (en) |
ZA (1) | ZA9711100B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277362B1 (en) | 1999-10-26 | 2001-08-21 | Isw, Inc. | After shave treatment preparation |
US20030049283A1 (en) * | 2001-08-31 | 2003-03-13 | Vandell Victor E. | Scalp desensitizing formulation |
US20050019298A1 (en) * | 2003-04-14 | 2005-01-27 | The Procter & Gamble Company | Transfer-resistant cosmetic compositions |
US20080206359A1 (en) * | 2007-02-23 | 2008-08-28 | Nikita Wilson | Day and Night Composition and method for treating Pseudofolliculitis Barbae |
US20110201578A1 (en) * | 2010-02-14 | 2011-08-18 | Nyangenya Maniga | Composition and methods for the treatment of pseudofolliculitis barbae and skin irritation |
US20120164096A1 (en) * | 2009-08-12 | 2012-06-28 | Jose Andres Prieto Alonso | Liquid shaving preparation |
WO2012135404A1 (en) | 2011-03-30 | 2012-10-04 | The Gillette Company | Method of viewing a surface |
US20130255711A1 (en) * | 2012-03-30 | 2013-10-03 | Zotos International, Inc. | Hair treatment and revitalizing composition and methods |
US20180207085A1 (en) * | 2015-07-15 | 2018-07-26 | Bakel Srl | Cosmetic composition |
US10463597B2 (en) | 2012-05-22 | 2019-11-05 | Conopco, Inc. | Personal care composition |
CN113093251A (en) * | 2021-03-18 | 2021-07-09 | 中国电子科技集团公司第五十四研究所 | High-precision indoor positioning method based on carrier phase of pseudolite |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2368541B1 (en) | 2010-03-26 | 2011-12-21 | The Procter & Gamble Company | Method of depilation and depilatory kit |
EP2559420B1 (en) * | 2011-08-17 | 2014-10-15 | The Procter and Gamble Company | Effective depilatory article |
CN104321046A (en) * | 2012-05-22 | 2015-01-28 | 荷兰联合利华有限公司 | Personal care composition comprising a colling active and a copolymer comprising acrylamidopropyltrimonium chloride |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944939A (en) * | 1987-12-14 | 1990-07-31 | Moore Milton D | Shaving preparation for treatment and prevention of PFB (Ingrown Hairs) |
US5567428A (en) * | 1993-08-27 | 1996-10-22 | The Procter & Gamble Company | Topical personal care composition containing polysiloxane-grafted adhesive polymer and drying aid |
US5652274A (en) * | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2186220A1 (en) * | 1972-05-05 | 1974-01-11 | Lewis John | Skin lotion - contg isopropylidene glycerol |
US4228163A (en) * | 1979-03-30 | 1980-10-14 | Dermik Laboratories | Method for treating pseudofolliculitis barbae |
US5380530A (en) * | 1992-12-29 | 1995-01-10 | Whitehill Oral Technologies | Oral care composition coated gum |
DE69530418T2 (en) * | 1994-12-21 | 2004-03-11 | Cosmederm Technologies, San Diego | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION |
-
1996
- 1996-12-12 US US08/766,395 patent/US5853709A/en not_active Expired - Fee Related
-
1997
- 1997-12-08 EP EP97951521A patent/EP0957895A4/en not_active Withdrawn
- 1997-12-08 AU AU55146/98A patent/AU5514698A/en not_active Abandoned
- 1997-12-08 IL IL13042297A patent/IL130422A0/en unknown
- 1997-12-08 CA CA002274812A patent/CA2274812A1/en not_active Abandoned
- 1997-12-08 JP JP52677998A patent/JP2001505913A/en active Pending
- 1997-12-08 BR BR9713576-3A patent/BR9713576A/en not_active IP Right Cessation
- 1997-12-08 AP APAP/P/1999/001601A patent/AP9901601A0/en unknown
- 1997-12-08 NZ NZ336621A patent/NZ336621A/en unknown
- 1997-12-08 WO PCT/US1997/022044 patent/WO1998025581A1/en not_active Application Discontinuation
- 1997-12-10 ZA ZA9711100A patent/ZA9711100B/en unknown
-
1999
- 1999-06-11 NO NO992851A patent/NO992851L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944939A (en) * | 1987-12-14 | 1990-07-31 | Moore Milton D | Shaving preparation for treatment and prevention of PFB (Ingrown Hairs) |
US5652274A (en) * | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
US5567428A (en) * | 1993-08-27 | 1996-10-22 | The Procter & Gamble Company | Topical personal care composition containing polysiloxane-grafted adhesive polymer and drying aid |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277362B1 (en) | 1999-10-26 | 2001-08-21 | Isw, Inc. | After shave treatment preparation |
US20030049283A1 (en) * | 2001-08-31 | 2003-03-13 | Vandell Victor E. | Scalp desensitizing formulation |
US20050019298A1 (en) * | 2003-04-14 | 2005-01-27 | The Procter & Gamble Company | Transfer-resistant cosmetic compositions |
US20080206359A1 (en) * | 2007-02-23 | 2008-08-28 | Nikita Wilson | Day and Night Composition and method for treating Pseudofolliculitis Barbae |
US20120164096A1 (en) * | 2009-08-12 | 2012-06-28 | Jose Andres Prieto Alonso | Liquid shaving preparation |
US20110201578A1 (en) * | 2010-02-14 | 2011-08-18 | Nyangenya Maniga | Composition and methods for the treatment of pseudofolliculitis barbae and skin irritation |
WO2012135404A1 (en) | 2011-03-30 | 2012-10-04 | The Gillette Company | Method of viewing a surface |
US20130255711A1 (en) * | 2012-03-30 | 2013-10-03 | Zotos International, Inc. | Hair treatment and revitalizing composition and methods |
US9283156B2 (en) * | 2012-03-30 | 2016-03-15 | Zotos International, Inc. | Hair treatment and revitalizing composition and methods |
US10463597B2 (en) | 2012-05-22 | 2019-11-05 | Conopco, Inc. | Personal care composition |
US20180207085A1 (en) * | 2015-07-15 | 2018-07-26 | Bakel Srl | Cosmetic composition |
US11013681B2 (en) * | 2015-07-15 | 2021-05-25 | Bakel Srl | Cosmetic composition |
CN113093251A (en) * | 2021-03-18 | 2021-07-09 | 中国电子科技集团公司第五十四研究所 | High-precision indoor positioning method based on carrier phase of pseudolite |
Also Published As
Publication number | Publication date |
---|---|
WO1998025581A1 (en) | 1998-06-18 |
AU5514698A (en) | 1998-07-03 |
EP0957895A1 (en) | 1999-11-24 |
JP2001505913A (en) | 2001-05-08 |
IL130422A0 (en) | 2000-06-01 |
CA2274812A1 (en) | 1998-06-18 |
NZ336621A (en) | 1999-10-28 |
AP9901601A0 (en) | 1999-09-30 |
BR9713576A (en) | 2000-03-14 |
ZA9711100B (en) | 1998-06-15 |
NO992851L (en) | 1999-07-29 |
EP0957895A4 (en) | 2000-04-05 |
NO992851D0 (en) | 1999-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4867967A (en) | Method for the treatment of pseudofolliculitis barbae | |
US4758599A (en) | Clear, hydroalcoholic aftershave lotion which moisturizes, conditions, and prevents irritation | |
KR101420599B1 (en) | Compositions containing anti-acne agents and the use thereof | |
US5853709A (en) | Shaving composition and method for preventing pseudofolliculitis barbae | |
JPH026321B2 (en) | ||
EP0215108B1 (en) | Compositions for treating acne vulgaris and methods of making same | |
EP1216696A2 (en) | Method for reducing the appearance of dark circles under the eyes | |
EP1295593A1 (en) | Skin cleanser containing anti-aging active | |
US20120207812A1 (en) | Skincare compositions comprising salicyclic acid | |
US20030095991A1 (en) | Treatment for skin | |
US5435997A (en) | Topical agent and method for the treatment of pseudofolliculitis barbae | |
EP1729719A1 (en) | Composition comprising sodium silicate for use in the treatment of dry skin conditions | |
JPH11139951A (en) | Cosmetic | |
EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
JP2006524199A (en) | Cosmetic peeling method | |
MXPA99005520A (en) | Shaving composition and method for preventing pseudofolliculitis barbae | |
US6861051B2 (en) | 1,2-propylene glycol skin preparation solution and method of use thereof | |
US20040204492A1 (en) | Topical composition and method for treating seborrheic dermatitis | |
JPH10273424A (en) | Cosmetic for hair | |
JP2826141B2 (en) | Dandruff inhibitor composition | |
WO2015095001A1 (en) | Skin cleansing composition with a deposition component | |
JPS635010A (en) | Cosmetic | |
JPH10273422A (en) | Cosmetic for hair | |
OH | Empirical formula: C4 H9 O7 Al2 Cl N4 | |
JPH04139112A (en) | Hair-treatment agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JOHNSON PRODUCTS CO., INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILLIS, ISAAC;DARKWA, ADU GYAMFI;VILLANUEVA, APOLONIO L.;REEL/FRAME:008340/0424;SIGNING DATES FROM 19961206 TO 19961211 |
|
AS | Assignment |
Owner name: IVAX CORPORATION A CORP. OF FL., FLORIDA Free format text: SECURITY AGREEMENT;ASSIGNOR:JOHNSON PRODUCTS CO., INC. A CORP. OF FL.;REEL/FRAME:009328/0772 Effective date: 19980714 |
|
AS | Assignment |
Owner name: WILLIS, I. LLC, GEORGIA Free format text: CONDITIONAL ASSIGNMENT;ASSIGNOR:JOHNSON PRODUCTS CO., INC.;REEL/FRAME:009545/0873 Effective date: 19971216 |
|
AS | Assignment |
Owner name: FOOTHILL CAPITAL CORPORATION, AS COLLATERAL AGENT, Free format text: ASSIGNMENT OF SECURITY AGREEMENT;ASSIGNOR:IVAX CORPORATION;REEL/FRAME:009564/0361 Effective date: 19980827 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: NORWEST BANK MINNESOTA, N.A., AS AGENT FOR QUANTUM Free format text: SECURITY AGREEMENT;ASSIGNOR:JOHNSON PRODUCTS COMPANY, INC.;REEL/FRAME:009693/0849 Effective date: 19981208 |
|
AS | Assignment |
Owner name: ISAAC WILLIS, GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JOHNSON PRODUCTS CO.,INC.;REEL/FRAME:009737/0437 Effective date: 19990127 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20021229 |